All releases

Jun 06, 2016

Verseon Corporation (“Verseon” or the “Company”)

Verseon to Present Latest Anticoagulant Results at Bio 2016

Fremont, Calif.— Verseon Corporation's (AIM: VSN) Dr. David Kita, Vice President of Research and Development, will present the latest data on Verseon's new class of anticoagulants at the 2016 BIO international Convention in San Francisco on Tuesday, 7 June. Dr. Kita's presentation will include the latest data on pharmacological safety assessment and the establishment of dose response in preclinical efficacy models. This new collection of data will form an important part of Verseon's upcoming Investigational New Drug (IND) application for this program.

About Verseon’s Anticoagulant Program

Verseon's new class of anticoagulants are part of a growing portfolio of drug programs being developed with the aid of its proprietary, computational drug discovery platform. The novel small-molecule direct thrombin inhibitors (DTIs) act through reversible covalent inhibition. This unique mode of action that leads to novel pharmacology, including lower bleeding liability as seen in multiple preclinical tests. In addition to efficacy and lower bleeding risk, Verseon's new class of anticoagulants also has pharmacokinetic properties suitable for oral dosing.

About Verseon’s anticoagulation program

Verseon’s potent, highly selective, oral direct thrombin inhibitors act through reversible covalent inhibition, a unique mode of action. Preclinical studies show that Verseon’s inhibitors act as effective anticoagulants in multiple efficacy studies, but do not disrupt platelet function. This unique feature could explain their observed low bleeding risk. One of Verseon’s lead candidates furthermore shows very low renal clearance, a highly desirable property for patients with impaired renal function.

About Verseon

Verseon Corporation (www.verseon.com, AIM: VSN) is a technology-based pharmaceutical company that employs its proprietary, computational drug discovery platform to develop novel therapeutics that are unlikely to be found using conventional methods. The Company is applying its platform to a growing drug pipeline and currently has three active drug programs in the areas of anticoagulation, diabetic macular edema, and oncology.

Note to Editors

Dr. David Kita will be available for interviews at the BIO international Convention in San Francisco to discuss this new collection of data.

- Ends -

For further information please contact

Verseon Corporation www.verseon.com
Arthur Shmurun / Amy Thai +1 (510) 225 9000

For financial and business media enquiries, please contact

Abchurch Communications Limited (PR Advisers)
Jamie Hooper / Alex Shaw +44 (0) 20 7398 7719

For trade and pharma media enquiries, please contact

Vane Percy & Roberts
Simon Vane Percy +44 (0) 1737 821 890

CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook,” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions, and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors.